Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,exchangeDataDelayedBy,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IMRA,75594000.0,17640500,7115000,,-10257000,,-10257000,3165000,0,-10280000,-10280000,,,,,,0,0,10280000,0,23000,,-10257000,-10257000,181945000.0,6093000.0,75594000.0,200000.0,81687000.0,18000.0,-106370000.0,1000.0,308000.0,53441000.0,5503000.0,1000.0,1018000.0,80361000.0,22151000.0,3001000.0,,18315000,1030000,18303000,460000,-4820000,472000,5743000,-13020000,25000,-12000,1002000,-12000,74858000.0,en-US,US,EQUITY,True,Delayed Quote,PRE,USD,NMS,IMARA Inc.,us_market,4,NasdaqGS,IMARA Inc.,USD,259076,86728,0.71000004,0.17530864,4.05 - 29.915,-25.155,-0.8408825,4.05,29.915,1620736200,1628771400,1629117000,-3.11,0,-1.5305468,5.196857,-0.43685675,-0.08406172,7.839348,-3.0793476,-0.39280662,83968784,15,America/New_York,EDT,-14400000,False,False,-0.62629926,4.71 - 4.82,4.79,0.0,0.0,10,10,finmb_331138302,4.76,1630526403,-0.029999733,4.82,4.82,4.71,40795,,,,29.915,4.05,5.1969,7.8393,259.08k,86.73k,17.64M,,6.24M,13.93%,87.73%,805.43k,9.39,17.52%,4.57%,785.24k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-29.05%,-49.12%,,,,,-44.53M,-44.4M,,,75.59M,4.28,847k,1.12,14.60,,-40.89M,-25.51M,Value,02116,Healthcare,27,"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,617 206 2020,MA,1609372800,United States,http://imaratx.com,86400,116 Huntington Avenue,Biotechnology,6th Floor
t-1,IMRA,84435000.0,17640500,8959000,,-11518000,,-11518000,2591000,0,-11550000,-11550000,,,,,,0,0,11550000,0,32000,,-11518000,-11518000,180526000.0,6407000.0,84435000.0,,90842000.0,18000.0,-96113000.0,4000.0,88000.0,47698000.0,6247000.0,4000.0,349000.0,90405000.0,40524000.0,1971000.0,160000.0,21208000,85000,21212000,597000,2283000,597000,13540000,-8269000,23000,-12000,858000,4000,84158000.0,en-US,US,EQUITY,True,Delayed Quote,PRE,USD,NMS,IMARA Inc.,us_market,4,NasdaqGS,IMARA Inc.,USD,259076,86728,0.71000004,0.17530864,4.05 - 29.915,-25.155,-0.8408825,4.05,29.915,1620736200,1628771400,1629117000,-3.11,0,-1.5305468,5.196857,-0.43685675,-0.08406172,7.839348,-3.0793476,-0.39280662,83968784,15,America/New_York,EDT,-14400000,False,False,-0.62629926,4.71 - 4.82,4.79,0.0,0.0,10,10,finmb_331138302,4.76,1630526403,-0.029999733,4.82,4.82,4.71,40795,,,,29.915,4.05,5.1969,7.8393,259.08k,86.73k,17.64M,,6.24M,13.93%,87.73%,805.43k,9.39,17.52%,4.57%,785.24k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-29.05%,-49.12%,,,,,-44.53M,-44.4M,,,75.59M,4.28,847k,1.12,14.60,,-40.89M,-25.51M,Value,02116,Healthcare,27,"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,617 206 2020,MA,1609372800,United States,http://imaratx.com,86400,116 Huntington Avenue,Biotechnology,6th Floor
t-2,IMRA,94698000.0,17640500,9533000,,-12423000,,-12423000,2961000,0,-12494000,-12494000,,,,,,0,0,12494000,0,71000,,-12423000,-12423000,179251000.0,5477000.0,94698000.0,,100175000.0,18000.0,-84595000.0,24000.0,88000.0,34158000.0,5310000.0,24000.0,376000.0,99711000.0,61931000.0,1886000.0,167000.0,-10282000,340000,-10282000,135000,1119000,207000,-20493000,-10346000,25000,-72000,593000,4000,94401000.0,en-US,US,EQUITY,True,Delayed Quote,PRE,USD,NMS,IMARA Inc.,us_market,4,NasdaqGS,IMARA Inc.,USD,259076,86728,0.71000004,0.17530864,4.05 - 29.915,-25.155,-0.8408825,4.05,29.915,1620736200,1628771400,1629117000,-3.11,0,-1.5305468,5.196857,-0.43685675,-0.08406172,7.839348,-3.0793476,-0.39280662,83968784,15,America/New_York,EDT,-14400000,False,False,-0.62629926,4.71 - 4.82,4.79,0.0,0.0,10,10,finmb_331138302,4.76,1630526403,-0.029999733,4.82,4.82,4.71,40795,,,,29.915,4.05,5.1969,7.8393,259.08k,86.73k,17.64M,,6.24M,13.93%,87.73%,805.43k,9.39,17.52%,4.57%,785.24k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-29.05%,-49.12%,,,,,-44.53M,-44.4M,,,75.59M,4.28,847k,1.12,14.60,,-40.89M,-25.51M,Value,02116,Healthcare,27,"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,617 206 2020,MA,1609372800,United States,http://imaratx.com,86400,116 Huntington Avenue,Biotechnology,6th Floor
t-3,IMRA,106296000.0,17640500,7869000,,-10204000,,-10204000,2433000,0,-10302000,-10302000,,,,,,0,0,10302000,0,98000,,-10204000,-10204000,178402000.0,5021000.0,106296000.0,,111317000.0,18000.0,-72172000.0,48000.0,324000.0,54651000.0,4848000.0,48000.0,400000.0,110593000.0,51624000.0,1669000.0,173000.0,-32401000,-291000,-32408000,9593000,677000,11239000,-32071000,-9256000,25000,-1646000,537000,-7000,105745000.0,en-US,US,EQUITY,True,Delayed Quote,PRE,USD,NMS,IMARA Inc.,us_market,4,NasdaqGS,IMARA Inc.,USD,259076,86728,0.71000004,0.17530864,4.05 - 29.915,-25.155,-0.8408825,4.05,29.915,1620736200,1628771400,1629117000,-3.11,0,-1.5305468,5.196857,-0.43685675,-0.08406172,7.839348,-3.0793476,-0.39280662,83968784,15,America/New_York,EDT,-14400000,False,False,-0.62629926,4.71 - 4.82,4.79,0.0,0.0,10,10,finmb_331138302,4.76,1630526403,-0.029999733,4.82,4.82,4.71,40795,,,,29.915,4.05,5.1969,7.8393,259.08k,86.73k,17.64M,,6.24M,13.93%,87.73%,805.43k,9.39,17.52%,4.57%,785.24k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-29.05%,-49.12%,,,,,-44.53M,-44.4M,,,75.59M,4.28,847k,1.12,14.60,,-40.89M,-25.51M,Value,02116,Healthcare,27,"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.",Boston,617 206 2020,MA,1609372800,United States,http://imaratx.com,86400,116 Huntington Avenue,Biotechnology,6th Floor
